FDA Proposes Budget Increase and Regulatory Reforms for 2027
The FDA has proposed a budget increase for 2027, with President Trump allocating $7.23 billion, marking a 3.2% rise from the previous year. This increase is part of a broader initiative to transition the FDA from a reactionary to a proactive system, as outlined by Commissioner Marty Makary. The budget aims to facilitate new pathways for drug development, enhance national security, and promote transparency. A significant aspect of the proposal is the permanent authorization of the rare pediatric disease priority review voucher program, which incentivizes the development of therapies for rare diseases in children. Additionally, the FDA plans to introduce a 'clinical trial notification pathway' to streamline the process for launching Phase 1 trials in the U.S., potentially reducing costs and regulatory burdens for smaller companies. 
